Compared to the highs of investment seen by the sector over the past couple of years, it has felt a much harsher environment in which to raise capital in 2022. The huge reduction in number and value of IPOs onto Nasdaq; the vast majority of biotechs listing post-Covid trading down and a drop in private capital investment, particularly in later rounds have created a gloomy feel in many quarters.
Despite this however, there have been many success stories, funding rounds secured, start-ups formed and deals done. Investment levels are not out of keeping with the steady trajectory pre-pandemic.…
It has been reported many times how growth, deals and collaborations are frequently stimulated via your network. Success is not simply about who you know’, although that is helpful absolutely. Based on a matrix of market insight, what you know, who you know and of course who they know is much more likely to deliver great outcomes.
For the majority of One Nucleus members, the Greater Boston cluster is an ecosystem of critical interest. Many connections exist already of course, but our intention at One Nucleus is always to seek…
Guest post by simon@needtobreathe.co.uk t: 07917191123
Leading diverse multidisciplinary teams, building trusted relationships with partners in science, establishing working collaborations, problem solving, generating new ideas, delivering complex projects, working toward a shared vision, having an environment where people want to come and work. Strong communication sits at the core of all of these things.
I’d like to share with you a piece of research that I find immensely useful when delivering leadership or communication development programmes, it will assist anyone who is…
Guest blog post by Victoria English, Editor, MedNous, Evernow Publishing Ltd
It is often said that cell and gene therapies are a ‘process’ rather than typical drugs. This is based on the fact that their success depends on the quality of their starting materials and how they are manufactured. This could be an autologous chimeric antigen receptor (CAR) T cell-based gene therapy, or any one of the many allogeneic products in clinical development. Manufacturing is the key strategic issue for developers of these therapies, according to speakers at the On Helix annual meeting in Cambridge, UK…
Take Part in this Workplace Survey from One Nucleus Member, Singular Talent
There’s change in the air. We’re predicting that your work and workplace will see momentous changes to meet what people expect from their employer.
Why?
Employees are looking for not only flexibility at work but a need for more autonomy. How this will affect leadership and longstanding working practices in management raises some interesting questions … it’s poised to change daily life at work for you, your team, and your manager…
And there’s yet more signs of evolution in the…
Blog by Alicia Gailliez, Business Development Manager, One Nucleus
You probably will not have read many blogs recently that start with a forest fire analogy, especially one targeted towards a Life Science audience, but here goes! On my recent trip to Yellowstone National Park, we learnt about the fires of 1988. Although devastating, the fires were an unprecedented chance to study the ecological impacts in an ecosystem and it was found that the environment would regenerate in a different way and one that could sustain a greater diversity of vegetation. This re-orientation can be…
Blog by Tony Jones, CEO, One Nucleus
January 2021 saw the launch of the One Nucleus Virtual Innovation Centre (VIC) created to provide a means for growing life science R&D companies to connect with and leverage the breadth of the One Nucleus ecosystem. A complementary offering to the variety of Innovation Centre, Accelerator and Incubator-style initiatives that are established and collated at a national level in the BIA Innovation Map, recognising that the need for support isn’t essentially time or set programme limited and requires those businesses to integrate into a coordinated…
Guest blog post by Chris Cooper, Scientific Specialist II, Immunotoxicology & Immunology, Labcorp Early Development Laboratories Ltd
In our previous post, we outlined the dangers of Cytokine Release Syndrome (CRS) and the importance of preclinical Cytokine Release Assays (CRAs) when developing monoclonal antibodies (mAbs) that interact with the patient’s immune system. In this second post, we describe the different kinds of assays in use and how these may fit into your drug development program. An alternative type of CRA, peripheral blood mononuclear cell (PBMC) blood…
Guest blog by Dave Mead, Director of Business Development, Isogenica Limited
I recently joined One Nucleus ’ BioWednesday panel to debate whether using Government R&D incentives are worth it.
So, are they? As a growing biotech company, Isogenica Limited has experience in accessing grant opportunities and other R&D incentives. Yet, for many start-ups, it can be a steep learning curve to work out what’s available and the best use of precious time and resources. Alongside panellists from Octane OC and EY, I collated the following useful…
Guest blog by Grace Gregory, Student, University of Manchester
I'm Grace and I am one of two students at the University of Manchester funded by NF2 BioSolutions UK. People with Neurofibromatosis Type 2 (NF2) often have many tumours that develop in the central nervous system along the spine and brain requiring risky surgeries over a lifetime with few alternatives.
The aim of my PhD is to investigate potential therapeutic avenues to reduce the number of surgeries needed and provide more treatment options to those with NF2.
I am currently looking at immune cells such as T…